Cardiovascular effects of phosphodiesterase type 5 inhibitors

Journal of Sexual Medicine

Volumn 6, Issue 3, 2009, Pages 658-674

  Vlachopoulos, Charalambos ^a   Ioakeimidis, Nikolaos ^a   Rokkas, Konstantinos ^a   Stefanadis, Christodoulos ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Cardiovascular System; Erectile Dysfunction; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

C REACTIVE PROTEIN; CYCLIC GMP; ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; NITRIC OXIDE; PADGEM PROTEIN; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROPIONYLCARNITINE; SILDENAFIL; TADALAFIL; VARDENAFIL; VASCULAR CELL ADHESION MOLECULE 1;

ANTIOXIDANT ACTIVITY; ARTERY DILATATION; ARTERY DISEASE; CARDIOVASCULAR EFFECT; CONGENITAL HEART DISEASE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC PRECONDITIONING; LUNG BLOOD VESSEL; MEDLINE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PENILE FIBROSIS; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SICKLE CELL ANEMIA; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

EID: 61649110304     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.01107.x     Document Type: Review

References (117)

1. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:3C-12C.
2. Rhoden EL, Riedner CE, Fornari A, Fuchs SC, Ribeiro EP. Evaluation of the association between lower urinary tract symptoms and erectile dysfunction, considering its multiple risk factors. J Sex Med 2008 [Epub ahead of print].
3. Chitale S, Collins R, Hull S, Smith E, Irving S. Is the current practice providing an integrated approach to the management of LUTS and ED in primary care? An audit and literature review. J Sex Med 2007;4:1713-25.
4. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008;5:2170-8.
5. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, placebo-controlled trial. J Urol 2007;177:1071-7.
6. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7.
7. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
8. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-22.
9. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL, Champion HC, Kass DA. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 2007;115:2159-67.
10. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St. Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Michelakis ED. Phosphodiesteras type 5 (PDE5) is highly expressed in the hypertrophied human right ventricle and acute inhibition of PDE5 improves contractility. Circulation 2007;116:238-48.
11. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, Yoshida K, Kukreja RC. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K (ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 2007;42:453-8.
12. Kukreja RC. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. Br J Pharmacol 2007;150:538-40.
13. Carson CC. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 2005;96:37M-41M.
14. Piccirillo G, Nocco M, Lionetti M, Moisè A, Naso C, Marigliano V, Cacciafesta M. Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002;143:703-10.
15. Siepmann M, Rauh R, Dill O, Agelink MW, Mueck-Weymann M. The effects of sildenafil on heart rate variability in healthy subjects. J Cardiovasc Pharmacol 2007;50:598-600.
16. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-6.
17. Jackson G, Montorsi P, Cheitlin MD. Cardiovascular safety of sildenafil citrate (Viagra): An updated perspective. Urology 2006;68:47-60.
18. Traverse JH, Chen YJ, Du R, Bache RJ. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. Circulation 2000;102:2997-3002.
19. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002;40:1232-42.
20. Tawakol A, Aziz K, Migrino R, Watkowska J, Zusman R, Alpert NM, Fischman AJ, Gewirtz H. Effects of sildenafil on myocardial blood flow in humans with ischemic heart disease. Coron Artery Dis 2005;16:443-9.
21. Weinsaft JW, Hickey K, Bokhari S, Shahzad A, Bedding A, Costigan TM, Warner MR, Emmick JT, Bergmann SR. Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. Coron Artery Dis 2006;17:493-9.
22. Vlachopoulos C, Hirata K, O'Rourke MF. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 2003;8:243-8.
23. Rosenkranz S. Pulmonary hypertension: Current diagnosis and treatment. Clin Res Cardiol 2007;96:527-41.
24. Kirsch M, Kemp-Harper B, Weissmann N, Grimminger F, Schmidt HH. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling. FASEB J 2008;22:30-40.
25. Patel MD, Katz SD. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. Am J Cardiol 2005;96:47M-51M.
26. Rossi R, Nuzzo A, Lattanzi A, Coppi F, Modena MG. Sildenafil improves endothelial function in patients with pulmonary hypertension. Pulm Pharmacol Ther 2008;21:172-7.
27. Tsai BM, Turrentine MW, Sheridan BC, Wang M, Fiore AC, Brown JW, Meldrum DR. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg 2006;81:272-8.
28. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances low-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-51.
29. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002;25:1336-9.
30. Kimura M, Higashi Y, Hara K, Noma K, Sasaki S, Nakagawa K, Goto C, Oshima T, Yoshizumi M, Chayama K. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 2003;41:1106-10.
31. Vlachopoulos C, Tsekoura D, Alexopoulos N, Panagiotakos D, Aznaouridis K, Stefanadis C. Type 5 Phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. Am J Hypertens 2004;17:1040-4.
32. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-22.
33. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: A human in vivo study. Circulation 2005;111:742-6.
34. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005;96:1436-40.
35. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006;48:622-7.
36. Mazo E, Gamidov S, Iremashvili V. The effect of vardenafil on endothelial function of brachial and cavernous arteries. Int J Impot Res 2006;18:464-9.
37. Foresta C, Ferlin A, De Toni L, Lana A, Vinanzi C, Galan A, Caretta N. Circulating endothelial progenitor cells and endothelial function after chronic tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006;18:484-8.
38. Bocchio M, Pelliccione F, Passaquale G, Mihalca R, Necozione S, Desideri G, Francavilla F, Ferri C, Francavilla S. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis 2008;196:313-9.
39. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: A pilot study. Int J Impot Res 2007;19:200-7.
40. Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Vinanzi C, Ferlin A. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: Effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol 2007;51:1411-7.
41. Yugar-Toledo JC, Ferreira-Melo SE, Consolim-Colombo FM, Irigoyen MC, Coelho OR, Moreno H Jr. Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension. Nitric Oxide 2007;16:315-21.
42. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007;50:2136-44.
43. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, Rosano GM. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 2008;25:37-44.
44. AttinàTM, Malatino LS, Maxwell SR, Padfield PL, Webb DJ. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. J Hypertens 2008;26:501-7.
45. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease. Int J Clin Pract 2005;59:225-9.
46. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Tsekoura D, Vasiliadou C, Stefanadi E, Askitis A, Stefanadis C. Arterial function and intima-media thickness in hypertensive patients with erectile dysfunction. J Hypertens 2008;26:1829-36.
47. Agrawal V, Ellins E, Donald A, Minhas S, Halcox J, Ralph DJ. Systemic vascular endothelial dysfunction in Peyronie's disease. J Sex Med 2008 [Epub ahead of print].
48. Miner M, Billups KL. Erectile dysfunction and dyslipidemia: Relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med 2008;5:1066-78.
49. Komori K, Tsujimura A, Takao T, Matsuoka Y, Miyagawa Y, Takada S, Nonomura N, Okuyama A. Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/cyclic guanosine 3′,5′-monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells. J Sex Med 2008;5:1623-35.
50. Behr-Roussel D, Oudot A, Caisey S, Coz OL, Gorny D, Bernabé J, Wayman C, Alexandre L, Giuliano FA. Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. Eur Urol 2008;53:1272-81.
51. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: Role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol 2005;68:226-32.
52. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
53. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H. European network for non-invasive investigation of large arteries. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
54. Agabiti-Rosei E, Mancia G, O'Rourke MF, Roman MJ, Safar ME, Smulyan H, Wang JG, Wilkinson IB, Williams B, Vlachopoulos C. Central blood pressure measurements and antihypertensive therapy: A consensus document. Hypertension 2007;50:154-60.
55. Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 2006;316:654-61.
56. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, Toutouza M, Stefanadis C. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005;112:2193-200.
57. Prisant LM. Phosphodiesterase-5 inhibitors and their hemodynamic effects. Curr Hypertens Rep 2006;8:345-51.
58. Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, Berk BC, Yan C. Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: A mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol 2005;38:175-84.
59. Toblli JE, Cao G, Lombraña A, Rivero M. Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan. J Sex Med 2007;4:1291-303.
60. Chiu YJ, Reid IA. Effect of sildenafil on renin secretion in human subjects. Exp Biol Med 2002;227:620-5.
61. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Vasiliadou C, Alexopoulos N, Stefanadi E, Askitis A, Stefanadis C. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 2006;27:2640-8.
62. Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: Common links. Eur Urol 2007;52:1590-600.
63. Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, Gandini L, Buchetti B, Lenti L, Jannini EA, Lenzi A. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: A double-blind, placebo-controlled study. Eur Urol 2007;52:1768-76.
64. Jeremy JY, Koupparis A, Muzaffar S, Persad R, Angelini GD, Shukla N. Is the therapeutic action of sildenafil mediated partly through the inhibition of superoxide formation? BJU Int 2005;95:930-1.
65. Aziz MT, Mostafa T, Atta H, Rashed L, Marzouk SA, Obaia EM, Sabry D, Hassouna AA, El-Shehaby AM, Aziz AT. The role of PDE5 inhibitors in heme oxygenase-cGMP relationship in rat cavernous tissues. J Sex Med 2008;5:1636-45.
66. Muzaffar S, Shukla N, Srivastava A, Angelini G, Jeremy J. Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol 2005;146:109-17.
67. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003;112:77-86.
68. Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis. J Am Coll Cardiol 2006;47:1471-7.
69. Li L, Jiang Q, Zhang L, Ding G, Gang Zhang Z, Li Q, Ewing JR, Lu M, Panda S, Ledbetter KA, Whitton PA, Chopp M. Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res 2007;1132:185-92.
70. Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J, Gonzalez-Cadavid NF. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod 2007;76:915-23.
71. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9.
72. GalièN, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
73. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Phosphodiesterase type 5 inhibitors: Non-erectile dysfunction cardiovascular events. In: Carson C, Goldstein I, Kirby R, eds. Textbook of erectile dysfunction. 2nd edition. Informa Healthcare; 2008.
74. Croom KF, Curran MP, Abman SH, Channick RN, Heresi GA, Rubin LJ, Torbicki A. Sildenafil: A review of its use in pulmonary hypertension. Drugs 2008;68:383-97.
75. Sayin T, Ozenci M. Sustained long-term benefit of sildenafil in primary pulmonary hypertension. Acta Cardiol 2007;62:47-9.
76. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555-62.
77. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study. J Am Coll Cardiol 2004;44:1488-96.
78. Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis of high-altitude illness. Chest 2008;133:744-55.
79. Perimenis P. Sildenafil for the treatment of altitude-induced hypoxaemia. Expert Opin Pharmacother 2005;6:835-7.
80. Bates MG, Thompson AA, Baillie JK. Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema. Curr Opin Investig Drugs 2007;8:226-31.
81. Schwarz ER, Kapur V, Bionat S, Rastogi S, Gupta R, Rosanio S. The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. Int J Impot Res 2008;20:85-91.
82. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: Expanding roles in cardiovascular regulation. Circ Res 2007;101:1084-95.
83. Hryniewicz K, Dimayuga C, Hudaihed A, Androne AS, Zheng H, Jankowski K. Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci 2005;108:331-8.
84. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005;111:1601-10.
85. Montorsi P, Ravagnani PM, Galli S, Salonia A, Briganti A, Werba JP, Montorsi F. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol 2006;50:721-31.
86. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, Salonia A, DehòF, Rigatti P, Montorsi F, Fiorentini C. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: The COBRA trial. Eur Heart J 2006;27:2632-9.
87. Vlachopoulos C, Ioakeimidis N, Stefanadis C. Erectile dysfunction and coronary artery disease: A relationship for disclosure. Hellenic J Cardiol 2008;49:1-6.
88. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, Carson C 3rd, Cheitlin M, Debusk R, Fonseca V, Ganz P, Goldstein I, Guay A, Hatzichristou D, Hollander JE, Hutter A, Katz S, Kloner RA, Mittleman M, Montorsi F, Montorsi P, Nehra A, Sadovsky R, Shabsigh R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313-21.
89. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: The day after. Eur Urol 2007;51:75-88.
90. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J 2002;4:H32-H47.
91. Mittleman MA, Maclure M, Lewis MA, Hall GC, Moore N, Giuliano F, Porst H, Hedelin H, Martin-Morales A, Sobel RE, Reynolds R, Glasser DB. Cardiovascular outcomes among sildenafil users: Results of the International Men's Health Study. Int J Clin Pract 2008;62:367-73.
92. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: A randomized crossover trial. JAMA 2002;287:719-25.
93. Gazzaruso C, Solerte SB, Pujia A, Coppola A, Vezzoli M, Salvucci F, Valenti C, Giustina A, Garzaniti A. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: A potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008;51:2040-4.
94. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/ American Heart Association. J Am Coll Cardiol 1999;33:273-82.
95. Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao K, Yoshimura M, Motoyama T, Inobe Y, Kawano H. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 1996;94:266-71.
96. Fung E, Fiscus RR, Yim AP, Angelini GD, Arifi AA. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest 2005;128:3065-73.
97. Parker JD, Bart BA, Webb DJ, Koren MJ, Siegel RL, Wang H, Malhotra B, Jen F, Glue P. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med 2007;35:1863-8.
98. Jackson G, Martin E, McGing E, Cooper A. Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. J Sex Med 2005;2:513-6.
99. Park HJ, Park NC, Shim HB, Park JK, Lee SW, Park K, Kim SW, Moon KH, Lee DH, Yoon SJ. An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. J Sex Med 2008 [Epub ahead of print].
100. Patterson D, McInnes GT, Webster J, Mitchell MM, Macdonald TM. Influence of a single dose of 20mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. Br J Clin Pharmacol 2006;62:280-7.
101. Grover-Páez F, Villegas Rivera G, Guillén Ortíz R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract 2007;78:136-40.
102. Suetomi T, Kawai K, Hinotsu S, Joraku A, Oikawa T, Sekido N, Miyanaga N, Shimazui T, Akaza H. Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men. J Sex Med 2008;5:1443-50.
103. Celermajer DS, Cullen S, Deanfield J. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993;87:440-6.
104. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007;120:301-5.
105. Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N, Trehan V, Tyagi S. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: A preliminary observational study. Circulation 2006;114:1807-10.
106. Lim ZS, Salmon AP, Vettukattil JJ, Veldtman GR. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. Int J Cardiol 2007;118:178-82.
107. Hong P, Pope JE, Ouimet JM, Rullan E, Seibold JR. Erectile dysfunction associated with scleroderma: A case-control study of men with scleroderma and rheumatoid arthritis. J Rheumatol 2004;3:508-13.
108. Proietti M, Aversa A, Letizia C, Rossi C, Menghi G, Bruzziches R, Merla A, Spera G, Salsano F. Erectile dysfunction in systemic sclerosis: Effects of long-term inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 2007;34:1712-7.
109. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, Simonneau G, SUPER Study Group. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-22.
110. Galiè N, Manes A, Farahani KV, Pelino F, Palazzini M, Negro L, Romanazzi S, Branzi A. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005;14:713-7.
111. Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, Erdmann E, Rosenkranz S. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006;166:231-3.
112. Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Clin Pharmacol Ther 2007;81:503-9.
113. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med 2008;5:1244-50.
114. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006;3:1077-84.
115. Machado RF, Martyr S, Kato GJ, Barst RJ, Anthi A, Robinson MR, Hunter L, Coles W, Nichols J, Hunter C, Sachdev V, Castro O, Gladwin MT. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005;130:445-53.
116. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007;110:2166-72.
117. Senthilkumar A, Smith RD, Khitha J, Arora N, Veerareddy S, Langston W, Chidlow JH Jr, Barlow SC, Teng X, Patel RP, Lefer DJ, Kevil CG. Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway. Arterioscler Thromb Vasc Biol 2007;27:1947-54.